RE:RE:RE:FTC blockage of Amgen's US$28 BLN takeover of Horizon“Relatively few leading drugs have been developed within the largest pharmaceutical companies,” Khan said.
The FTC's position on drug development concerning the largest pharmaceutical companies gives whatever BP acquirer of ONCY's Phase 3 product indication portfolio the opportunity to take pelareorep in-house and develop pelareorep as its own. Such an acquisition of ONCY's pelareorep would address the FTC's criticism of BP's under performing track record of internal product development.